Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE&#039;s STAT-Net

Browse by...

Deposit

Highlights

More informations

Title		Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net
Authors		Timsit, Jean-François de Kraker, Marlieke E A Sommer, Harriet Weiss, Emmanuel Bettiol, Esther Wolkewitz, Martin Nikolakopoulos, Stavros Wilson, David Harbarth, Stéphan Juergen show all authors [1 - 9]
Published in		Intensive Care Medicine. 2017, vol. 43, no. 7, p. 1002-1012
Abstract		In this era of rising antimicrobial resistance, slowly refilling antibiotic development pipelines, and an aging population, we need to ensure that randomized clinical trials (RCTs) determine the added benefit of new antibiotic agents effectively and in a valid way, especially for severely ill patients. Unfortunately, universally accepted endpoints for the evaluation of new drugs in severe infections are lacking.
Identifiers		DOI: 10.1007/s00134-017-4802-4 PMID: 28466147
Full text		Article (Published version) (1 MB) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Groupe Harbarth Stephan (Staphylocoques dorés résistants à la méthicilline) (866)
Citation (ISO format)		TIMSIT, Jean-François et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net. In: Intensive Care Medicine, 2017, vol. 43, n° 7, p. 1002-1012. doi: 10.1007/s00134-017-4802-4 https://archive-ouverte.unige.ch/unige:99523